Using hyaluronic acid-functionalized pH stimuli-responsive mesoporous silica nanoparticles for targeted delivery to CD44-overexpressing cancer cells

Zhihui Wang,* Yongfeng Tian,* Hua Zhang, Yanmei Qin, Dong Li, Li Gan, Fanhong Wu Department of Pharmaceutical Engineering, School of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai, People’s Republic of China *These authors contributed equally...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wang ZH, Tian YF, Zhang H, Qin YM, Li D, Gan L, Wu FH
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://doaj.org/article/99011b6b2eb8498bb2527a611b74da56
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Zhihui Wang,* Yongfeng Tian,* Hua Zhang, Yanmei Qin, Dong Li, Li Gan, Fanhong Wu Department of Pharmaceutical Engineering, School of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai, People’s Republic of China *These authors contributed equally to this work Abstract: In this study, novel hyaluronic acid-pH stimuli-responsive lipid membrane mesoporous silica nanoparticles (HA-PL-MSNs) were designed and assembled, with the chemotherapeutic agent doxorubicin (DOX) as the model drug. HA-PL-MSNs exhibited a well-defined mesostructure covered by lipid bilayer and particle size of ~150 nm. The drug loading capacity was up to ~18.2%. DOX release could be effectively retained by the lipid bilayer in pH 7.4 buffer and exhibited a pH-triggered burst release in the acidic condition. Confocal laser scanning microscopy and fluorescence-activated cell sorting showed that HA-PL-MSNs exhibited higher cellular uptake efficiency via CD44 receptor-mediated endocytosis compared with PL-MSNs in HeLa cells. In vitro cytotoxicity studies demonstrated that HA-PL-MSNs could effectively enhance the targeted delivery of DOX and restrain the growth of HeLa cells. This might provide a promising alternative for the development of a targeted anticancer drug delivery system. Keywords: mesoporous silica nanoparticles, hyaluronic acid, pH-sensitive lipid membrane, CD44 receptor, HeLa cells